Antisense binding enhanced by tertiary interactions: binding of phosphorothioate and N3'-->P5' phosphoramidate hexanucleotides to the catalytic core of a group I ribozyme from the mammalian pathogen Pneumocystis carinii

Biochemistry
Stephen M TestaD H Turner

Abstract

Pneumocystis carinii is the most common lethal opportunistic pathogen infecting Acquired Immune Deficiency Syndrome (AIDS) patients, and more effective therapeutics for it are needed. P. carinii, but not humans, contain RNA self-splicing group I introns, so these functionally important RNAs are potential anti-fungal targets. In vitro, d(ATGACT), which mimics the 3' end of the 5' exon of a conserved ribosomal RNA group I intron from mouse-derived Pneumocystis carinii binds to a ribozyme that is a truncated form of this intron. The binding is about 30,000 times tighter than expected for simple base-pairing because binding is enhanced by tertiary interactions. Here we report the effects of modifying the phosphodiester backbone of d(ATGACT) with phosphorothioate and of d(ATGAC)rU with N3'-->P5' phosphoramidate linkages. The enhancement of binding by tertiary interactions is not substantially decreased, and in some cases is increased when single Rp and Sp phosphorothioate substitutions are made, although overall binding is weaker by up to 6-fold. A mixture of 5' exon mimic isomers that each contain five phosphorothioate linkages binds to the ribozyme at least 14-fold less tightly than the corresponding phosphodiester mimic. In contr...Continue Reading

References

Jan 1, 1985·Annual Review of Biochemistry·F Eckstein
Sep 1, 1986·Journal of Biochemical and Biophysical Methods·E Wickstrom
Jul 15, 1974·Journal of Molecular Biology·P N BorerO C Uhlenbeck
Jul 9, 1993·Journal of Medicinal Chemistry·J F MilliganJ C Martin
Jan 7, 1993·Nature·J A PiccirilliT R Cech

❮ Previous
Next ❯

Citations

Feb 27, 1999·Current Opinion in Biotechnology·M AfsharG Varani
Jul 27, 2001·Nucleic Acids Research·N K Banavali, A D MacKerell
Jun 18, 2005·Nucleic Acids Research·Jennifer M KalishPeter M Glazer
Mar 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·S M TestaD H Turner
Aug 29, 2002·Journal of the American Chemical Society·Tatsuo OhmichiNaoki Sugimoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.